Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VTGN VistaGen Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: VTGN
Price (delayed)
$2.27
Market cap
$66.19M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.67
Enterprise value
$566,054
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and
Highlights
The company's debt fell by 29% YoY and by 12% QoQ
The net income has dropped by 75% year-on-year and by 9% since the previous quarter
VTGN's quick ratio has dropped by 73% year-on-year and by 31% since the previous quarter
Key stats
What are the main financial stats of VTGN
Market
Valuations
Earnings
Shares outstanding
29.16M
Market cap
$66.19M
Enterprise value
$566,054
Price to earnings (P/E)
N/A
Price to book (P/B)
0.93
Price to sales (P/S)
144.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.16
Revenue
$486,000
Gross profit
$486,000
Operating income
-$55.97M
Net income
-$51.42M
EBIT
-$51.41M
EBITDA
-$50.78M
Free cash flow
-$42.29M
Per share
Balance sheet
Liquidity
EPS
-$1.67
EPS diluted
-$1.67
Free cash flow per share
-$1.37
Book value per share
$2.44
Revenue per share
$0.02
TBVPS
$2.73
Total assets
$84.34M
Total liabilities
$13.95M
Debt
$1.51M
Equity
$70.39M
Working capital
$69.46M
Debt to equity
0.02
Current ratio
6.51
Quick ratio
6.38
Net debt/EBITDA
1.29
Margins
Efficiency
Dividend
EBITDA margin
-10,447.7%
Gross margin
100%
Net margin
-10,579.8%
Operating margin
-11,517.1%
Return on assets
-52.4%
Return on equity
-58.9%
Return on invested capital
-592.7%
Return on capital employed
-71.7%
Return on sales
-10,578.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VTGN stock price
How has the VistaGen Therapeutics stock price performed over time
Intraday
-4.62%
1 week
-7.72%
1 month
2.71%
1 year
-41.94%
YTD
-23.05%
QTD
13.5%
Financial performance
How have VistaGen Therapeutics's revenue and profit performed over time
Revenue
$486,000
Gross profit
$486,000
Operating income
-$55.97M
Net income
-$51.42M
Gross margin
100%
Net margin
-10,579.8%
The net income has dropped by 75% year-on-year and by 9% since the previous quarter
The company's operating income has shrunk by 70% YoY and by 6% QoQ
The company's net margin has shrunk by 56% QoQ
VistaGen Therapeutics's revenue has shrunk by 54% YoY and by 30% QoQ
Price vs fundamentals
How does VTGN's price correlate with its fundamentals
Growth
What is VistaGen Therapeutics's growth rate over time
Valuation
What is VistaGen Therapeutics stock price valuation
P/E
N/A
P/B
0.93
P/S
144.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.16
VistaGen Therapeutics's EPS has decreased by 13% from the previous quarter and by 10% YoY
The price to book (P/B) is 67% lower than the 5-year quarterly average of 3.0 and 2% lower than the last 4 quarters average of 1.0
The equity has decreased by 38% YoY and by 13% QoQ
VistaGen Therapeutics's revenue has shrunk by 54% YoY and by 30% QoQ
The price to sales (P/S) is 20% higher than the last 4 quarters average of 126.0
Efficiency
How efficient is VistaGen Therapeutics business performance
VistaGen Therapeutics's ROS has plunged by 56% from the previous quarter
The ROE has decreased by 41% YoY and by 22% from the previous quarter
The company's return on assets fell by 39% YoY and by 20% QoQ
The company's return on invested capital rose by 35% YoY and by 6% QoQ
Dividends
What is VTGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VTGN.
Financial health
How did VistaGen Therapeutics financials performed over time
VTGN's quick ratio has dropped by 73% year-on-year and by 31% since the previous quarter
The current ratio has plunged by 72% YoY and by 30% from the previous quarter
The company's debt is 98% lower than its equity
The equity has decreased by 38% YoY and by 13% QoQ
The company's debt fell by 29% YoY and by 12% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.